Crysvita Purple Book BLA 761068

BLA number
761068
Proprietary names
Crysvita
Proper names
burosumab-twza
Applicant
Kyowa Kirin, Inc.
Center
CDER
First observed release
2020-05-01
Latest observed release
2026-06-01
Newest archive release
2026-06-01
FDA patent list
No patents listed in the captured FDA patent list; source updated 2025-06-11
Coverage
Present in newest release

Latest Known Product Presentations#

Product, Proprietary name, Proper name table
ProductProprietary nameProper nameLicense typeStrengthDosage formRoutePresentationMarketingLicensureApprovalPatent list provided
001Crysvitaburosumab-twza351(a)10MG/MLInjectionSubcutaneousSingle-Dose VialRxLicensed2018-04-17
002Crysvitaburosumab-twza351(a)20MG/MLInjectionSubcutaneousSingle-Dose VialRxLicensed2018-04-17
003Crysvitaburosumab-twza351(a)30MG/MLInjectionSubcutaneousSingle-Dose VialRxLicensed2018-04-17

Published Patent List#

No patents for this BLA were listed in the FDA Purple Book patent list captured from the source updated 2025-06-11.

Official Monthly Change Events#

Release, Event, Product table
ReleaseEventProductNameLicense typeStatusApplicant
2020-08-01U001Crysvita351(a)RxKyowa Kirin, Inc.
2020-08-01U002Crysvita351(a)RxKyowa Kirin, Inc.
2020-08-01U003Crysvita351(a)RxKyowa Kirin, Inc.
2020-05-01R001Crysvita351(a)RxKyowa Kirin, Inc.
2020-05-01R002Crysvita351(a)RxKyowa Kirin, Inc.
2020-05-01R003Crysvita351(a)RxKyowa Kirin, Inc.

Observed Product State History#

Release, Product, Name table
ReleaseProductNameLicense typeMarketingLicensureApproval
2020-05-01001Crysvita351(a)RxLicensed2018-04-17
2020-05-01002Crysvita351(a)RxLicensed2018-04-17
2020-05-01003Crysvita351(a)RxLicensed2018-04-17